# PROPHYLOCHIP-PRODIGE 15

Source: https://onco.cc/trials/prophylochip/  
OnCo record `prophylochip` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Reopening the abdomen to look for and wash out invisible disease did not help, and one patient in four had a serious complication.

## Summary

PROPHYLOCHIP randomised 150 patients at 23 French hospitals who were at high risk of colorectal peritoneal metastases (resected synchronous localised peritoneal metastases, resected ovarian metastases or a perforated tumour) and who were disease-free after six months of adjuvant chemotherapy, to systematic second-look surgery with oxaliplatin HIPEC or to surveillance. After a median 50.8 months, three-year disease-free survival was 53 percent with surveillance against 44 percent with second-look surgery (hazard ratio 0.97, 95% CI 0.61 to 1.56). Twenty-nine of 71 patients in the surgery group (41 percent) had grade 3 to 4 complications. Standard surveillance is enough.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-24
- Registry id: NCT01226394
- Phase: 3
- Setting: Patients at high risk of colorectal peritoneal metastases after resection and six months of adjuvant chemotherapy: systematic second-look surgery with HIPEC against surveillance
- Sponsor: Gustave Roussy
- Enrolled: 150
- Result: Three-year disease-free survival 44 percent with second-look surgery and HIPEC against 53 percent with surveillance.
- Outcomes: Disease-free survival at 3 years: Second-look surgery plus HIPEC 44 percent vs Surveillance 53 percent, HR 0.97

## Sources

- ClinicalTrials.gov NCT01226394: https://clinicaltrials.gov/study/NCT01226394
- PROPHYLOCHIP-PRODIGE 15: second-look surgery plus HIPEC versus surveillance (Lancet Oncology 2020): https://doi.org/10.1016/S1470-2045(20)30322-3

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [HIPEC / PIPAC (intraperitoneal chemotherapy)](https://onco.cc/technologies/hipec/)
- drugs: [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Mitomycin C](https://onco.cc/drugs/mitomycin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- institutions: [Gustave Roussy](https://onco.cc/institutions/gustave-roussy/)
- trials: [COLOPEC](https://onco.cc/trials/colopec/), [Netherlands Cancer Institute HIPEC trial](https://onco.cc/trials/netherlands-hipec/), [PRODIGE 7](https://onco.cc/trials/prodige-7/)
- terms: [Colorectal cancer: the failed and stopped programmes, and why](https://onco.cc/terms/colorectal-failed-programmes/)

---
JSON: https://onco.cc/api/v1/entities/prophylochip.json